JP2022512830A5 - - Google Patents

Info

Publication number
JP2022512830A5
JP2022512830A5 JP2021523064A JP2021523064A JP2022512830A5 JP 2022512830 A5 JP2022512830 A5 JP 2022512830A5 JP 2021523064 A JP2021523064 A JP 2021523064A JP 2021523064 A JP2021523064 A JP 2021523064A JP 2022512830 A5 JP2022512830 A5 JP 2022512830A5
Authority
JP
Japan
Prior art keywords
group
substituted
alkylene
antibody
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512830A (ja
JP7629400B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/079188 external-priority patent/WO2020084115A1/en
Publication of JP2022512830A publication Critical patent/JP2022512830A/ja
Publication of JP2022512830A5 publication Critical patent/JP2022512830A5/ja
Application granted granted Critical
Publication of JP7629400B2 publication Critical patent/JP7629400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523064A 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体 Active JP7629400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382759.1 2018-10-25
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (3)

Publication Number Publication Date
JP2022512830A JP2022512830A (ja) 2022-02-07
JP2022512830A5 true JP2022512830A5 (cg-RX-API-DMAC10.html) 2024-03-21
JP7629400B2 JP7629400B2 (ja) 2025-02-13

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523064A Active JP7629400B2 (ja) 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体

Country Status (37)

Country Link
US (1) US12653900B2 (cg-RX-API-DMAC10.html)
EP (1) EP3870234B1 (cg-RX-API-DMAC10.html)
JP (1) JP7629400B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210086669A (cg-RX-API-DMAC10.html)
CN (1) CN113226377B (cg-RX-API-DMAC10.html)
AR (1) AR117657A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019368687B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021007718A2 (cg-RX-API-DMAC10.html)
CA (1) CA3117268C (cg-RX-API-DMAC10.html)
CL (1) CL2021001039A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021006838A2 (cg-RX-API-DMAC10.html)
DK (1) DK3870234T3 (cg-RX-API-DMAC10.html)
EA (1) EA202191131A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21035414A (cg-RX-API-DMAC10.html)
ES (1) ES2939494T3 (cg-RX-API-DMAC10.html)
FI (1) FI3870234T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20230275T1 (cg-RX-API-DMAC10.html)
HU (1) HUE061606T2 (cg-RX-API-DMAC10.html)
IL (1) IL282577B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20210083B1 (cg-RX-API-DMAC10.html)
LT (1) LT3870234T (cg-RX-API-DMAC10.html)
MA (1) MA59661B1 (cg-RX-API-DMAC10.html)
MD (1) MD3870234T2 (cg-RX-API-DMAC10.html)
MX (1) MX2021004746A (cg-RX-API-DMAC10.html)
MY (1) MY206221A (cg-RX-API-DMAC10.html)
PH (1) PH12021550930A1 (cg-RX-API-DMAC10.html)
PL (1) PL3870234T3 (cg-RX-API-DMAC10.html)
PT (1) PT3870234T (cg-RX-API-DMAC10.html)
RS (1) RS64068B1 (cg-RX-API-DMAC10.html)
SA (1) SA521421855B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202104154WA (cg-RX-API-DMAC10.html)
SI (1) SI3870234T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300076T1 (cg-RX-API-DMAC10.html)
TW (1) TWI824043B (cg-RX-API-DMAC10.html)
UA (1) UA129803C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020084115A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202103478B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3615544T (lt) * 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
WO2021218896A1 (zh) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 海鞘素类衍生物及其制备方法与医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
IL308389A (en) * 2021-05-19 2024-01-01 Pharma Mar Sa Dosing regimens for acubactadine
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
CN118878690B (zh) * 2023-11-28 2026-01-09 南京大学 一种抗地高辛纳米抗体的制备及其应用
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228597A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
WO2025233522A1 (en) * 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin
WO2026098196A1 (zh) * 2024-11-08 2026-05-15 映恩生物科技(上海)有限公司 海鞘素类化合物、其偶联物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2005281359A1 (en) 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック, インコーポレイテッド 抗体薬剤結合体および方法
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP2404912A3 (en) 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
WO2011147828A1 (en) 2010-05-25 2011-12-01 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
IT201700041639A1 (it) 2017-04-13 2018-10-13 M C Automations S R L Dispositivo di trasferimento per macchine incartatrici di prodotti dolciari
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CR20220581A (es) * 2020-04-21 2023-01-09 Pharma Mar Sa Conjugados de anticuerpos de fármacos

Similar Documents

Publication Publication Date Title
HRP20230275T1 (hr) Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina
JP7146031B2 (ja) 抗her2抗体-薬物コンジュゲート
US20240173427A1 (en) Glypican 3 antibodies and conjugates thereof
CN106456794B (zh) 接头药物与抗体的位点特异性缀合以及所得adc
BR112020020466A2 (pt) Conjugados de peptídeo de camptotecina
EP3271329B1 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
JP2023520930A (ja) 電荷多様性リンカー
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
RU2015156499A (ru) Конъюгаты антитела с лекарственным средством
JP2023515845A (ja) 抗-cd56抗体-薬物複合体およびその治療での使用
JP2023522259A5 (cg-RX-API-DMAC10.html)
JP2023515941A5 (cg-RX-API-DMAC10.html)
JP2023519776A5 (cg-RX-API-DMAC10.html)
CA3204418A1 (en) Linker-payloads and conjugates thereof
KR20250137203A (ko) 항체 약물 접합체
AU2019386945B9 (en) Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用
JP2022548530A5 (cg-RX-API-DMAC10.html)
CN120225226A (zh) B7-h3抗体药物偶联物及其应用
TH2101002347A (th) คอนจูเกตแอนติบอดียา (Drug Antibody Conjugates)
JP2024540536A5 (cg-RX-API-DMAC10.html)
CN119816522B (zh) 5t4抗体药物偶联物及其应用
WO2025226868A1 (en) Antibody drug conjugates and uses thereof
HK40058007A (en) Site-specific conjugation of linker drugs to antibodies and resulting adcs
JP2026507789A5 (cg-RX-API-DMAC10.html)